6 results about "Cell brain" patented technology

The application discloses application of a swertianol derivative in preparation of a glioma treatment drug and belongs to the technical field of medicines. The application finds that the compound has significant inhibitory activity on SF126, T98G, A172, U-87 MG, U251 and various glioma cell lines, and the activity is better than that of temozolomide, a commonly used clinical anti-glioma drug, and the compound has lower toxicity to normal brain cells. The application further provides a preparation method of the compound and a pharmaceutical composition containing the compound, and the pharmaceutical composition can be prepared into injection, tablets and various dosage forms. The application provides a new effective drug selection for the treatment of glioma, has a mature preparation process, various drug dosage forms and a wide clinical application prospect.

The application provides a construction method of a zebrafish model of diabetic cerebral hemorrhage sequelae for high-throughput drug screening, and belongs to the technical field of biotechnology.The first zebrafish model capable of comprehensively simulating the complex pathological phenotypes of clinical diabetic cerebral hemorrhage sequelae is successfully constructed, and the blank of the research model in the field is filled.The pathological changes of the model are highly consistent with the symptoms of the patients with clinical diabetic cerebral hemorrhage sequelae, such as glucose metabolism disorder, pancreatic beta cell damage, cerebral vascular injury and hemorrhage, brain cell apoptosis, inflammatory reaction and behavior abnormality, and the limitation that the existing single disease model cannot simulate the synergistic pathogenesis of diabetes and cerebral hemorrhage is overcome, so that a reliable experimental animal model is provided for high-throughput screening of active ingredients against the disease.

This system provides a high-resolution microelectrode neuronal stimulation system that allows control of the current intensity of any two electrodes, selectively stimulating brain cell tissue B in a target area T within a stimulation area A, reducing the complexity and cost of electrode placement, and achieving highly precise neuronal stimulation. [Solution] The high-resolution microelectrode neuron stimulation system includes at least two stimulation electrodes 10, a first control module 20, and a second control module 30. The outer circumferences of the multiple stimulation electrodes 10 are connected to form a stimulation area A. The first control module 20 has a first signal source 21 and at least two first switches 23, the first signal source 21 providing a first current having a first frequency. The second control module 30 has a second signal source 31 and at least two second switches 33, the second signal source 31 providing a second current having a second frequency.

The present disclosure relates to vectors, compositions, pharmaceutical compositions and kits providing brain cell-specific expression of reprogramming genes, such as Yamanaka factors Oct4, Sox2, Klf4 and c-Myc (OSKM). Methods and uses including the same for treating Alzheimer's disease and progeria by brain cell-specific expression of reprogramming genes, such as OSKM, are also provided.

This invention provides a pharmaceutical composition for improving memory function, relating to the field of pharmaceutical technology. The composition comprises vitamin B6, vitamin B12, lutein, anthocyanins, phosphatidylserine, docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), levodopa, benserazide, and selegiline. Vitamin B6, vitamin B12, lutein, anthocyanins, phosphatidylserine, DHA, and EPA nourish the brain; levodopa, benserazide, and selegiline are used for neuropharmacological treatment; anthocyanins, lutein, and EPA synergistically improve cerebral microcirculation, enhance blood oxygen supply, scavenge free radicals, reduce inflammation, and decrease brain cell aging and necrosis, thereby delaying the process of memory decline; levodopa, benserazide, and selegiline synergistically supplement and protect dopamine, with benserazide enhancing the bioavailability of levodopa and selegiline inhibiting dopamine degradation.